Secondary Erythrocytosis in Patients With Heart Failure on SGLT2 Inhibitors: Insights from a Multicenter “Real World” Study
Sodium glucose co-transporter 2 inhibitors (SGLT2-i) are one of the four pillars of guideline-directed medical therapy in all patients with heart failure according to the current guidelines1. Although SGLT2-i are known to increase hemoglobin (Hb) and hematocrit (Ht) levels, there is a lack of data on the burden of erythrocytosis in pivotal trials and real-world heart failure (HF) populations2-4. We have previously described a case of chronic HF with severe secondary, reversible SGLT2-i erythrocytosis in which the patient experienced HF exacerbation2.
Authors
- Dennis A. Hesselink (ORCID: https://orcid.org/0000-0003-1871-1962)
- Martijn Tukker (ORCID: https://orcid.org/0000-0001-5423-4433)
- Kadir ÇALIŞKAN (ORCID: https://orcid.org/0000-0001-7794-5991)
- Peter A.W. te Boekhorst (ORCID: https://orcid.org/0000-0002-3566-5016)
- René A. Tio (ORCID: https://orcid.org/0000-0003-1164-5827)
- Frank H. de Jong (ORCID: https://orcid.org/0000-0003-3578-1065)
- Behiye Özcan (ORCID: https://orcid.org/0000-0002-3475-0219)
- Joris A. Jansen
- Thomas Kok (ORCID: https://orcid.org/0009-0002-8772-3924)
- Melissa S Pherai
- Selina Özoğul
- Samantha Lenting
Institutions
- Radboud University Nijmegen (NL)
- Catharina Ziekenhuis (NL)
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
- Thorax Foundation (GR)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- The American Journal of Cardiology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1016/j.amjcard.2025.09.011
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00